Bank of New York Mellon Corp Purchases 475,934 Shares of Haleon plc (NYSE:HLN)

Bank of New York Mellon Corp grew its holdings in Haleon plc (NYSE:HLN - Free Report) by 29.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,071,017 shares of the company's stock after purchasing an additional 475,934 shares during the quarter. Bank of New York Mellon Corp's holdings in Haleon were worth $19,758,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. FMR LLC boosted its stake in Haleon by 5.8% in the third quarter. FMR LLC now owns 104,918,269 shares of the company's stock worth $1,110,035,000 after purchasing an additional 5,768,117 shares in the last quarter. Wellington Management Group LLP increased its holdings in Haleon by 49.9% in the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company's stock valued at $96,833,000 after purchasing an additional 3,046,841 shares during the last quarter. Douglas Lane & Associates LLC increased its holdings in Haleon by 1.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company's stock valued at $82,274,000 after purchasing an additional 161,865 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Haleon by 25.3% in the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company's stock valued at $53,791,000 after purchasing an additional 1,026,939 shares during the last quarter. Finally, Van ECK Associates Corp increased its holdings in Haleon by 13.5% in the fourth quarter. Van ECK Associates Corp now owns 3,509,400 shares of the company's stock valued at $33,480,000 after purchasing an additional 418,609 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company's stock.

Remove Ads

Haleon Stock Down 0.3 %

Shares of NYSE:HLN traded down $0.04 during mid-day trading on Friday, reaching $10.16. 7,990,718 shares of the stock were exchanged, compared to its average volume of 6,642,967. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The company has a market cap of $45.97 billion, a P/E ratio of 29.87, a P/E/G ratio of 2.82 and a beta of 0.25. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The stock's 50 day simple moving average is $9.74 and its 200-day simple moving average is $9.87.

Haleon (NYSE:HLN - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The firm had revenue of $3.54 billion during the quarter, compared to analysts' expectations of $3.38 billion. As a group, equities research analysts predict that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The business also recently declared a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This is a boost from Haleon's previous -- dividend of $0.05. This represents a yield of 1.6%. Haleon's dividend payout ratio is 58.97%.

Analysts Set New Price Targets

A number of research firms recently commented on HLN. Sanford C. Bernstein downgraded Haleon from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 8th. Morgan Stanley downgraded Haleon from an "overweight" rating to an "equal weight" rating in a report on Friday, January 10th. HSBC restated a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Hsbc Global Res downgraded Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a report on Monday, March 3rd. Six research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Haleon presently has a consensus rating of "Hold" and an average target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.